Blog

ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care

ESMO/LinkedIn

Jun 12, 2025, 18:30

ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Recent study results support the integration of Antibody Drug Conjugates (ADCs) into the first-line treatment for metastatic Breast Cancer.

Read the opinion by Paolo Tarantino in the ESMO Daily Reporter anylsing how the results from these key studies will impact the treatment course and what pending questions remain to be addressed.”

Paolo Tarantino, 2025 Yvonne’s Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:

“Multiple positive trials, one common feature: advancing the use of ADCs to earlier lines of treatment.

It’s happening fast, and it is producing meaningful clinical benefits. Yet, questions remain.

Thank you ESMO Daily for this interview!”

More posts featuring ESMO on OncoDaily.

ADCs Antibody drug conjugates Breast Cancer cancer Dana-Farber Cancer Institute ESMO ESMO Daily Reporter European Society for Medical Oncology OncoDaily Oncology Paolo Tarantino

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer